VLP Therapeutics

VLP is a biotech company with a mission to address unmet medical needs worldwide and expand the frontiers of vaccine treatment.

VLP's vision is to combat the 21st century global public health problems through revolutionary next generation i-αVLP (inserted alpha VLP) Technology.

VLPT was co-founded in 2013 by Wataru Akahata, Ryuji Ueno, and Sachiko Kuno. The company is headquartered in Gaithersburg, Maryland.


VLPT is currently engaged in research and development of a cancer treatment vaccine as well as prophylactic vaccines against malaria, dengue, and novel coronavirus disease (COVID-19) using VLPT's proprietary platform technologies.


VLP's malaria vaccine candidate VLPM01 clinical trial designed to evaluate the safety, tolerability, immunogenicity and experimental efficacy of VLPM01 in healthy, malaria-naïve adult volunteers.


VLPT is backed by MIYAKO Capital C, Nobelpharma Co., MUFG Bank, Sojitz Corporation, SK Impact Fund, RJ Fund, Konishiyasu Co., and others. The company raised $21M in Series A-1 round on Dec 27, 2021. This brings VLPT's total funding to $40.9M to date.



  • Year founded: 2013
  • Funding Info: $40.9M over 3 Rounds (Latest Funding Type: Series A-1)
  • Yearly Revenue: NA
  • Employee Size: 11-50
  • Business Valuation: NA
  • City/Town: Gaithersburg
  • State: Maryland
  • Country: United States
Related businesses